XFXiaosheng Fang

Xiaosheng Fang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiaosheng Fang has a total of 174 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prediction of prognosis and immunotherapy response of tryptophan metabolism genes in acute myeloid leukemia

    by Tantan Zhong, Meirui Zhang, Xinran Qi, Zhihui Qi, Peipei Li, Na Wang, Xianghua Wang, Panpan Feng, Xiaosheng Fang

    Background: Acute myeloid leukemia (AML) is an aggressive and heterogeneous disease, associated with significant morbidity and mortality rates. Tryptophan metabolism has been implicated in the development of several tumors. The immune landscape within the tumor microenvironment plays a pivotal role in both leukemogenesis and the determination of patient prognosis. Nonetheless, the influence of tryptophan metabolic patterns and corresponding immune signatures in AML remains largely unclear. Methods: Transcriptomic, genomic, and clinical data from TCGA were analyzed, and GSE71014 was used for external validation. Molecular subtypes were identified via consensus clustering of tryptophan metabolism–related genes (TRPRGs). Immune infiltration was quantified using ESTIMATE. A tryptophan-related prognostic risk score (TRPRS) was constructed using LASSO–Cox regression and evaluated for prognostic performance. Results: We characterized alterations in 39 TRPRGs across AML cohorts and delineated the clinical and tumor microenvironmental features of two molecular subtypes. First, a TRPRG-based scoring system was established, identifying seven candidate genes significantly associated with patient outcomes. After LASSO-Cox regression selection, six genes were incorporated into the final prognostic model, stratify overall survival risk. The TRPRS effectively stratified overall survival in both the TCGA and GEO cohorts and remained an independent prognostic factor after multivariate adjustment. High-TRPRS patients exhibited distinct immune characteristics and differential drug sensitivity patterns. Functional experiments demonstrated that HADH and ECHS1 promote AML cell proliferation and survival. Discussion: Our integrative analysis identified key tryptophan-metabolism–related genes in AML and developed a six-gene TRPRS capable of accurately distinguishing survival risk. This model not only provides mechanistic insights into AML progression but also offers a framework for individualized risk stratification and therapeutic guidance.

  • Open Access

    Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma

    by Qiqi Qiao, Bingyu Liu, Juanjuan Shang, Wenyue Sun, Xiaoli Zhou, Xiaosheng Fang, Shunfeng Hu, Xin Wang

    Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) is the most common extra-nodal DLBCL. Metabolism-related factors have been associated with tumor progression, but the relationship between abnormal metabolism and prognosis of PGI-DLBCL remains unelucidated. In our study, consensus clustering based on metabolism-related genes classified PGI-DLBCL patients into two metabolic subtypes, and poor prognosis was associated with immunosuppressive microenvironment. A prognostic signature based on five metabolism-related genes (APOE, ALDH6 A1, PLOD2, IKBKB and ALDH1B1) was developed. Patients in high-risk group had a worse prognosis, with an immunosuppressive microenvironment. Moreover, 159 PGI-DLBCL patients were enrolled and divided into training cohort (n = 87) and validation cohort (n = 72). Univariate and multivariate Cox regression analysis showed metabolism-related factors were independent prognostic factors in PGI-DLBCL. A novel model (A-IPI score) combining APOA and NCCN-IPI was developed, and A-IPI score was better than NCCN-IPI score in predicting the prognosis of PGI-DLBCL patients. Furthermore, immunohistochemistry showed that ALDH1B1 was highly expressed in PGI-DLBCL and patients with high ALDH1B1 expression displayed worse prognosis. Moreover, cell proliferation assay revealed that the treatment with IGUANA-1, ALDH1B1 inhibitor, suppressed cell proliferation in DLBCL and IGUANA-1 exerted synergistic anti-tumor effects with PI3K inhibitor duvelisib. Additionally, we found that immune scores, ESTIMATE scores, and stromal scores were higher and the immune checkpoints (CTLA-4, PD-1, PD-L1) were down-regulated in patients with high ALDH1B1 expression. Collectively, our study constructed a novel metabolism-related prognostic model and highlighted the potential of metabolism-related gene ALDH1B1 as prognostic biomarker and drug target in PGI-DLBCL, providing new insights for the development of precision therapies in PGI-DLBCL patients.


  • Open Access

    Ferroptosis: Potential therapeutic targets and prognostic predictions for acute myeloid leukemia (Review)

    by Wenlu Zhang, Wen Wen, Ran Tan, Meirui Zhang, Tantan Zhong, Jianhong Wang, Haiping Chen, Xiaosheng Fang

    Ferroptosis is a relatively recently discovered type of regulated cell death that is induced by iron‑dependent lipid peroxidation. The key contributing factors to ferroptosis are the loss of glutathione peroxidase 4 which is required for reversing lipid peroxidation, the buildup of redox‑active iron and the oxidation of phospholipids containing polyunsaturated fatty acids. Ferroptosis has been associated with a number of diseases, including cancers such as hepatocellular carcinoma, breast cancer, acute renal damage and neurological disorders such as Alzheimer's disease and Alzheimer's disease, and there may be an association between ferroptosis and acute myeloid leukemia (AML). The present review aims to describe the primary regulatory pathways of ferroptosis, and the relationship between ferroptosis and the occurrence and development of AML. Furthermore, the present review comprehensively summarizes the latest advances in the treatment and prognosis of ferroptosis in AML.


  • Open Access

    Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin

    by Yahan Li, Fansheng Kong, Guanchen Bai, Yujie Jiang, Wenlu Zhang, Xue Sun, Xiaohui Sui, Ying Li, Mei Ding, Dai Yuan, et al.

    Background: Eltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT).Methods: Forty-one HSCT patients received eltrombopag 50 mg/d from +1 day until PLT >50 × 109/L or 1 month after HSCT. Fifty-one patients in the same period received thrombopoietin (TPO) to promote PLT graft after HSCT and served as a control group.Results: A total of 51 patients who applied TPO during the same period were treated as a control. In the eltrombopag group, the median time to white blood cells (WBC) graft was 12 days (range, 10-17 days) and the PLT graft was 15 days (range, 10-30 days), whereas for the patients in the TPO group, the median time to WBC and PLT graft was 12 days (range, 9-23 days) and 15.5 days (range, 9-41 days), respectively. In the first month after HSCT, the median WBC count in the eltrombopag group was 4.41 × 109/L (range, 0.87-40.01 × 109/L) and the median PLT was 89x109/L (range, 30-401 × 109/L); the median WBC and PLT \counts in the TPO group were 4.65 × 109/L (range, 0.99-23.63 × 109/L) and 86 × 109/L (range, 5-512 × 109/L), respectively. Patients in the TPO or eltrombopag group did not experience serious side effects after drug administration, and the difference in side effects on liver and kidney function between the two groups was not statistically significant.Conclusion: Eltrombopag is safe and similarly promotes platelet engraftment to thrombopoietin after allogeneic HSCT.


  • Open Access

    NCAPD3 promotes diffuse large B-cell lymphoma progression through modulating SIRT1 expression in an H3K9 monomethylation-dependent manner

    by Tiange Lu, Juan Yang, Yiqing Cai, Mengfei Ding, Zhuoya Yu, Xiaosheng Fang, Xiangxiang Zhou, Xin Wang


  • Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets

    by Wen Wen, Wen-Lu Zhang, Ran Tan, Tan-Tan Zhong, Mei-Rui Zhang, Xiao-Sheng Fang

    Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30%-40% of non-Hodgkin lymphoma in adults. The mechanisms underlying DLBCL occurrence are extremely complex, and involve the B-cell receptor (BCR) and Toll-like receptor (TLR) signaling pathways, as well as genetic abnormalities and other factors. With the development of high-throughput sequencing, an increasing number of abnormal genes have been identified in DLBCL. Among them, the tumor protein p53 (TP53/p53) gene is important in DLBCL occurrence. Patients with DLBCL carrying TP53 gene abnormalities generally have poor prognosis and studies of p53 have potential to provide a better basis for their treatment. Normally, p53 is maintained at low levels through its interaction with murine double minute 2 (MDM2), and prevents tumorigenesis by mediating cell cycle arrest, apoptosis, and repair of damaged cells, among other processes. Therefore, the prognosis of patients with DLBCL harboring TP53 gene abnormalities (mutations, deletions, etc.) is poor, and targeting p53 for tumor therapy has become a research hotspot, following developments in molecular biology technologies. Current treatments targeting p53 mainly act by restoring the function or promoting degradation of mutant p53, and enhancing wild-type p53 protein stability and activity. Based on the current status of p53 research, exploration of existing therapeutic methods to improve the prognosis of patients with DLBCL with TP53 abnormalities is warranted.


  • Open Access

    NCAPD3 Prompts Diffuse Large B-Cell Lymphoma Progression through Modulating SIRT1 Expression in H3K9 Monomethylation-Dependent Manner

    by Tiange Lu, Xiangxiang Zhou, Juan Yang, Yiqing Cai, Mengfei Ding, Xiaomin Chen, Zhuoya Yu, Xiaosheng Fang, Xin Wang

    Disclosures. No relevant conflicts of interest to declare.Figure 1

  • Open Access

    ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells

    by Elaine Y. L. Chung, Giulio Sartori, Maurilio Ponzoni, Luciano Cascione, Valdemar Priebe, Zijun Y. Xu‐Monette, Xiaosheng Fang, Mingzhi Zhang, Carlo Visco, Alexandar Tzankov, et al.

    Summary: The transcriptional factor ETS1 is upregulated in 25% of diffuse large B cell lymphoma (DLBCL). Here, we studied the role of ETS1 phosphorylation at threonine 38, a marker for ETS1 activation, in DLBCL cellular models and clinical specimens. p‐ETS1 was detected in activated B cell‐like DLBCL (ABC), not in germinal centre B‐cell‐like DLBCL (GCB) cell lines and, accordingly, it was more common in ABC than GCB DLBCL diagnostic biopsies. MEK inhibition decreased both baseline and IgM stimulation‐induced p‐ETS1 levels. Genetic inhibition of phosphorylation of ETS1 at threonine 38 affected the growth and the BCR‐mediated transcriptome program in DLBCL cell lines. Our data demonstrate that ETS1 phosphorylation at threonine 38 is important for the growth of DLBCL cells and its pharmacological inhibition could benefit lymphoma patients.


  • Characteristics of Molecular Genetic Mutations and Their Correlation with Prognosis in Adolescent and Adult Patients with Acute Lymphoblastic Leukemia

    by Xue Sun, Xiaoqian Liu, Ying Li, Xue Shi, Yahan Li, Ran Tan, Yujie Jiang, Xiaohui Sui, Xueling Ge, Hongzhi Xu, et al.

    Introduction: The prognosis of acute lymphoblastic leukemia (ALL) in adolescents and adults is poor, and recurrence is an important cause of their death. Changes of genetic information play a vital role in the pathogenesis and recurrence of ALL; however, the impact of molecular genetic mutations on disease diagnosis and prognosis remains unexplored. This study aimed to explore the frequency spectrum of gene mutations and their prognostic significance, along with the minimal residual disease (MRD) level and hematopoietic stem cell transplantation (HSCT), in adolescent and adult patients aged ≥15 years with ALL. Methods: The basic characteristics, cytogenetics, molecular genetics, MRD level, treatment regimen, and survival outcome of patients with untreated ALL (≥15 years) were collected, and the correlation and survival analysis were performed using the SPSS 25.0 and R software. Results: This study included 404 patients, of which 147 were selected for next-generation sequencing (NGS). NGS results revealed that 91.2% of the patients had at least one mutation, and 67.35% had multiple (≥2) mutations. NOTCH1, PHF6, RUNX1, PTEN, JAK3, TET2, and JAK1 were the most common mutations in T-ALL, whereas FAT1, TET2, NARS, KMT2D, FLT3, and RELN were the most common mutations in B-ALL. Correlation analysis revealed the mutation patterns, which were significantly different between T-ALL and B-ALL. In the prognostic analysis of 107 patients with B-ALL, multivariate analysis showed that the number of mutations ≥5 was an independent risk factor for overall survival and the RELN mutation was an independent poor prognostic factor for event-free survival. Discussion: The distribution of gene mutations and the co-occurrence and repulsion of mutant genes in patients with ALL were closely related to the immunophenotype of the patients. The number of mutations ≥5 and the RELN mutation were significantly associated with poor prognosis in adolescent and adult patients with ALL.